Charles River Laboratories Net Long-Term Debt 2010-2025 | CRL
Charles River Laboratories annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Charles River Laboratories net long-term debt for the quarter ending June 30, 2025 was $0.076B, a 130.74% decline year-over-year.
- Charles River Laboratories net long-term debt for the twelve months ending June 30, 2025 was $-0.410B, a 19.8% decline year-over-year.
- Charles River Laboratories annual net long-term debt for 2024 was $-0.412B, a 447.23% increase from 2023.
- Charles River Laboratories annual net long-term debt for 2023 was $-0.075B, a 480.53% decline from 2022.
- Charles River Laboratories annual net long-term debt for 2022 was $0.02B, a 97.05% decline from 2021.
| Charles River Laboratories Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $-412 |
| 2023 | $-75 |
| 2022 | $20 |
| 2021 | $670 |
| 2020 | $31 |
| 2019 | $227 |
| 2018 | $554 |
| 2017 | $-136 |
| 2016 | $388 |
| 2015 | $75 |
| 2014 | $104 |
| 2013 | $-12 |
| 2012 | $-66 |
| 2011 | $-2 |
| 2010 | $198 |
| 2009 | $-36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.033B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.998B | 27.26 |
| CVS Health (CVS) | United States | $91.497B | 11.38 |
| Elevance Health (ELV) | United States | $69.898B | 9.40 |
| Cencora (COR) | United States | $56.203B | 18.72 |
| DiDi Global (DIDIY) | China | $27.392B | 22.39 |
| Natera (NTRA) | United States | $23.041B | 0.00 |
| Labcorp Holdings (LH) | United States | $22.877B | 18.18 |
| BioMerieux (BMXMF) | France | $17.423B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.582B | 0.00 |
| ICON (ICLR) | Ireland | $14.136B | 13.60 |
| Medpace Holdings (MEDP) | United States | $13.286B | 35.16 |
| CochLear (CHEOY) | Australia | $12.819B | 0.00 |
| Solventum (SOLV) | United States | $12.598B | 13.00 |
| Viatris (VTRS) | United States | $12.137B | 4.32 |
| Caris Life Sciences,�Inc (CAI) | United States | $10.751B | 0.00 |
| Revvity (RVTY) | United States | $10.357B | 18.25 |
| Avantor (AVTR) | United States | $9.006B | 13.21 |
| Sonic Healthcare (SKHHY) | Australia | $7.755B | 0.00 |
| HealthEquity (HQY) | United States | $7.635B | 33.44 |
| Bausch + Lomb (BLCO) | Canada | $5.151B | 34.64 |
| Sotera Health (SHC) | United States | $4.602B | 25.71 |
| BrightSpring Health Services (BTSG) | United States | $4.204B | 32.07 |
| Amplifon S.p.A (AMFPF) | Italy | $3.937B | 21.83 |
| GeneDx Holdings (WGS) | United States | $3.706B | 84.87 |
| Alignment Healthcare (ALHC) | United States | $3.232B | 0.00 |
| Concentras Parent (CON) | United States | $3.043B | 19.30 |
| Surgery Partners (SGRY) | United States | $2.913B | 36.65 |
| Organon (OGN) | United States | $2.386B | 2.60 |
| KindlyMD (NAKA) | United States | $2.230B | 0.00 |
| Premier (PINC) | United States | $2.169B | 20.05 |
| Progyny (PGNY) | United States | $1.999B | 42.27 |
| Ardent Health (ARDT) | United States | $1.793B | 6.92 |
| PACS (PACS) | United States | $1.769B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.515B | 25.65 |
| Pediatrix Medical (MD) | United States | $1.489B | 9.94 |
| Teladoc Health (TDOC) | United States | $1.394B | 0.00 |
| Omada Health (OMDA) | $1.360B | 0.00 | |
| Establishment Labs Holdings (ESTA) | $1.188B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.962B | 0.00 |
| Embecta (EMBC) | United States | $0.848B | 4.97 |
| AMN Healthcare Services Inc (AMN) | United States | $0.768B | 9.50 |
| CareDx (CDNA) | United States | $0.698B | 12.85 |
| Performant Healthcare (PHLT) | United States | $0.600B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.583B | 100.00 |
| Agilon Health (AGL) | United States | $0.526B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.517B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.491B | 0.00 |
| Nutex Health (NUTX) | United States | $0.491B | 7.43 |
| Auna S.A (AUNA) | Luxembourg | $0.466B | 6.99 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.461B | 0.00 |
| SBC Medicals (SBC) | United States | $0.424B | 9.27 |
| Enhabit (EHAB) | United States | $0.401B | 26.40 |
| So-Young (SY) | China | $0.399B | 0.00 |
| Oncology Institute (TOI) | United States | $0.325B | 0.00 |
| LifeMD (LFMD) | United States | $0.306B | 0.00 |
| Beauty Health (SKIN) | United States | $0.259B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.226B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.159B | 0.00 |
| DocGo (DCGO) | United States | $0.159B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.116B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.070B | 0.00 |
| Biodesix (BDSX) | United States | $0.065B | 0.00 |
| NeueHealth (NEUE) | United States | $0.059B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.037B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.024B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.016B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.005B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |